BioMarin Completes Acquisition of Amicus Therapeutics
Rhea-AI Summary
BioMarin (Nasdaq: BMRN) completed its acquisition of Amicus Therapeutics on April 27, 2026, in an all-cash deal at $14.50 per share, valuing the transaction at approximately $4.8 billion. The deal adds commercial therapies Galafold (migalastat) and Pombiliti + Opfolda, plus U.S. rights to Phase 3 candidate DMX-200. BioMarin plans to provide updated FY 2026 guidance on its Q1 earnings call on May 4, 2026.
AI-generated analysis. Not financial advice.
Positive
- Acquisition price: $14.50 per share in an all-cash transaction (~$4.8B equity)
- Adds commercial product Galafold (oral Fabry therapy) approved in >40 countries
- Adds Pombiliti + Opfolda combination for late-onset Pompe disease to portfolio
- Acquired U.S. rights to DMX-200, a Phase 3 candidate for FSGS
Negative
- All-cash purchase implies $4.8B immediate cash outflow and potential near-term financing impact
- Galafold U.S. approval is accelerated and contingent on confirmatory trials for continued approval
- Pombiliti carries boxed warnings and contraindication in pregnancy that may affect uptake
News Market Reaction – BMRN
On the day this news was published, BMRN gained 1.18%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BMRN fell 1.48% while close peers were mixed: BBIO up 2.83%, ASND up 2.31%, and IONS, EXEL, SMMT down modestly. With only one peer in momentum scanners and no common headlines, the move appears stock-specific.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | Amicus deal announced | Positive | +17.7% | Announced $4.8B Amicus acquisition adding revenue-generating rare disease therapies. |
| Jul 01 | Inozyme deal closed | Positive | +2.2% | Completed $270M Inozyme acquisition adding INZ-701 enzyme therapy program. |
| May 16 | Inozyme deal announced | Positive | +1.7% | Announced acquisition of Inozyme and late-stage ENPP1 Deficiency therapy INZ-701. |
Recent acquisition announcements and completions for BMRN have coincided with positive share reactions.
Over the past year, BioMarin has repeatedly used acquisitions to expand its rare disease franchise. The initial Amicus deal announcement on Dec 19, 2025 and both the announcement and completion of the Inozyme transaction in May and July 2025 all saw positive price reactions. Today’s completion of the Amicus acquisition continues this M&A strategy by adding marketed Fabry and Pompe therapies and additional late-stage pipeline assets.
Historical Comparison
In the past year, BMRN’s three acquisition headlines averaged a 7.22% gain. Today’s Amicus deal completion with a -1.48% move contrasts with those historically positive M&A reactions.
The Amicus transaction progressed from announcement in Dec 2025 to expected close in Q2 2026, while the Inozyme deal moved from signing to completion in 2025, reflecting a pattern of executing acquisitions to expand BioMarin’s rare disease portfolio.
Market Pulse Summary
This announcement confirms completion of the Amicus acquisition, adding marketed therapies for Fabry and Pompe diseases plus a Phase 3 asset in focal segmental glomerulosclerosis. Historically, BioMarin’s acquisition news produced average moves of about 7.22%, reflecting the strategic importance of M&A. Investors may track upcoming FY 2026 guidance, integration progress, and performance of Galafold and Pombiliti + Opfolda within the broader rare disease portfolio.
Key Terms
fabry disease medical
pompe disease medical
lysosomal storage diseases medical
alpha-galactosidase a medical
focal segmental glomerulosclerosis medical
phase 3 medical
enzyme replacement therapy medical
anaphylaxis medical
AI-generated analysis. Not financial advice.
Acquisition Adds Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease to BioMarin's Commercial Portfolio
BioMarin Expects to Provide Updated FY 2026 Guidance During its First Quarter Earnings Call, May 4, 2026
"The completion of the Amicus acquisition advances BioMarin's strategy to strengthen and diversify our growth profile while furthering our mission to deliver medicines for people living with rare diseases," said Alexander Hardy, President and Chief Executive Officer of BioMarin. "BioMarin's global scale, established commercial infrastructure, and advanced in‑house manufacturing capabilities build on Amicus' legacy and position us to bring Galafold and Pombiliti + Opfolda to more patients around the world."
About Galafold
Galafold® (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable galactosidase alpha gene (GLA) variants. In these patients, Galafold works by stabilizing the body's own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of people living with Fabry disease may have amenable GLA variants, though amenability rates within this range vary by geography. Galafold is approved in more than 40 countries around the world, including the
Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable GLA variant based on in vitro assay data.
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
ADVERSE REACTIONS: The most common adverse reactions reported with Galafold (≥
USE IN SPECIFIC POPULATIONS: There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus. It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition. Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis. The safety and effectiveness of Galafold have not been established in pediatric patients. To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For additional information about Galafold, including the full
About Pombiliti + Opfolda
Pombiliti + Opfolda, is a two-component therapy that consists of cipaglucosidase alfa-atga, a bis-M6P-enriched rhGAA that facilitates high-affinity uptake through the M6P receptor while retaining its capacity for processing into the most active form of the enzyme, and the oral enzyme stabilizer, miglustat, that's designed to reduce loss of enzyme activity in the blood.
POMBILITI in combination with OPFOLDA is indicated for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase (GAA) deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).
SAFETY INFORMATION
HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS: Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe hypersensitivity reaction occurs, POMBILITI should be discontinued immediately and appropriate medical treatment should be initiated. INFUSION-ASSOCIATED REACTIONS (IARs): If severe IARs occur, immediately discontinue POMBILITI and initiate appropriate medical treatment. RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS: Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function, may be at risk of serious exacerbation of their cardiac or respiratory status during POMBILITI infusion. See the full
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the
Forward-Looking Statements
This press release contains forward-looking statements about, among other things, the business prospects of Amicus Therapeutics (Amicus) and BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: the prospective benefits of the acquisition; expectations regarding Amicus' products, Galafold and Pombiliti + Opfolda; expectations regarding Amicus' product candidate, DMX-200, and its ongoing development; BioMarin's capital allocation strategy to leverage its financial strength to diversify its pipeline and add innovative new therapies for patients; BioMarin's plans for external innovation, including BioMarin's ability to execute additional transactions in future quarters; statements about BioMarin's future performance; and other statements that are not historical facts. Actual results could differ materially from those anticipated in these forward-looking statements. Except as required by law, each of BioMarin and Amicus assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent each of BioMarin's and Amicus' current expectations or beliefs concerning various future events that are subject to significant risks and uncertainties, may contain words such as "may," "will," "would," "could," "expect," "anticipate," "intend," "plan," "believe," "estimate," "project," "seek," "should," "strategy," "future," "opportunity," "potential" or other similar words and expressions indicating future results.
These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including, without limitation, with respect to: the effects of the acquisition on Amicus' or BioMarin's stock price and/or Amicus' or BioMarin's operating results; unknown or inestimable liabilities; the development, launch and commercialization of products and product candidates; the parties' ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period and that BioMarin and Amicus will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; obtaining and maintaining adequate coverage and reimbursement for BioMarin's or Amicus' products; the time-consuming and uncertain regulatory approval process; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients, including with respect to current and planned future clinical trials; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to BioMarin's or Amicus' business operations and financial results; the sufficiency of BioMarin's or Amicus' cash flows and capital resources; BioMarin's evaluation of the potential impact of the transaction on its financial results and financial guidance; BioMarin's or Amicus' ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the effects of the transaction on relationships with key third parties, including employees, customers, suppliers, other business partners or governmental entities, including the risk that the acquisition adversely affects employee retention; risks that the acquisition disrupts current plans and operations; any legal proceedings related to the acquisition; and other risks and uncertainties affecting BioMarin and Amicus, including those risk factors detailed in BioMarin's and Amicus' filings with the Securities and Exchange Commission (SEC), including, without limitation, the risk factors contained under the caption "Risk Factors" in BioMarin's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and Amicus' Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as such risk factors may be updated by any subsequent reports, as well as the Proxy Statement on Schedule 14A filed by Amicus (as amended and/or supplemented). Stockholders of BioMarin and Amicus are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin and Amicus are under no obligation, and expressly disclaim any obligation, to update (publicly or otherwise) or alter any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events or otherwise.
BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc. or its affiliates.
Contacts:
Investors
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558
Media
Marni Kottle
BioMarin Pharmaceutical Inc.
(415) 218-7111
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-completes-acquisition-of-amicus-therapeutics-302754256.html
SOURCE BioMarin Pharmaceutical Inc.